ADC Therapeutics (ADCT) Competitors $2.68 -0.01 (-0.19%) Closing price 03:59 PM EasternExtended Trading$2.70 +0.03 (+1.12%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADCT vs. PAHC, PHVS, ARDX, GPCR, AMPH, VERV, SYRE, AKBA, RCUS, and COLLShould you be buying ADC Therapeutics stock or one of its competitors? The main competitors of ADC Therapeutics include Phibro Animal Health (PAHC), Pharvaris (PHVS), Ardelyx (ARDX), Structure Therapeutics (GPCR), Amphastar Pharmaceuticals (AMPH), Verve Therapeutics (VERV), Spyre Therapeutics (SYRE), Akebia Therapeutics (AKBA), Arcus Biosciences (RCUS), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry. ADC Therapeutics vs. Its Competitors Phibro Animal Health Pharvaris Ardelyx Structure Therapeutics Amphastar Pharmaceuticals Verve Therapeutics Spyre Therapeutics Akebia Therapeutics Arcus Biosciences Collegium Pharmaceutical Phibro Animal Health (NASDAQ:PAHC) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation. Does the media prefer PAHC or ADCT? In the previous week, Phibro Animal Health had 9 more articles in the media than ADC Therapeutics. MarketBeat recorded 10 mentions for Phibro Animal Health and 1 mentions for ADC Therapeutics. Phibro Animal Health's average media sentiment score of 1.03 beat ADC Therapeutics' score of -0.50 indicating that Phibro Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADC Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Do institutionals & insiders believe in PAHC or ADCT? 99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by insiders. Comparatively, 5.4% of ADC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is PAHC or ADCT more profitable? Phibro Animal Health has a net margin of 2.68% compared to ADC Therapeutics' net margin of -197.64%. Phibro Animal Health's return on equity of 30.51% beat ADC Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Phibro Animal Health2.68% 30.51% 6.89% ADC Therapeutics -197.64%N/A -45.57% Do analysts prefer PAHC or ADCT? Phibro Animal Health presently has a consensus price target of $24.40, indicating a potential downside of 14.51%. ADC Therapeutics has a consensus price target of $7.75, indicating a potential upside of 189.72%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe ADC Therapeutics is more favorable than Phibro Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phibro Animal Health 2 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.83ADC Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, PAHC or ADCT? Phibro Animal Health has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, ADC Therapeutics has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. Which has stronger valuation & earnings, PAHC or ADCT? Phibro Animal Health has higher revenue and earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhibro Animal Health$1.02B1.14$2.42M$0.7836.59ADC Therapeutics$70.84M3.75-$157.85M-$1.45-1.84 SummaryPhibro Animal Health beats ADC Therapeutics on 10 of the 15 factors compared between the two stocks. Get ADC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADCT vs. The Competition Export to ExcelMetricADC TherapeuticsMED IndustryMedical SectorNYSE ExchangeMarket Cap$265.80M$2.98B$5.45B$20.61BDividend YieldN/A2.28%4.60%3.65%P/E RatioN/A17.1629.7827.95Price / Sales3.75171.23376.6288.33Price / CashN/A40.7324.8417.60Price / Book-1.278.898.604.60Net Income-$157.85M-$54.75M$3.26B$994.60M7 Day Performance-1.83%-2.08%0.55%0.27%1 Month Performance-15.35%1.89%1.41%-1.22%1 Year Performance0.56%8.52%36.52%14.31% ADC Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADCTADC Therapeutics1.5632 of 5 stars$2.68-0.2%$7.75+189.7%+1.5%$265.80M$70.84M0.00310Upcoming EarningsPAHCPhibro Animal Health4.1377 of 5 stars$27.14+3.9%$24.40-10.1%+59.6%$1.06B$1.02B34.801,940News CoveragePositive NewsAnalyst RevisionPHVSPharvaris1.6499 of 5 stars$21.24+6.2%$36.20+70.4%+25.1%$1.05BN/A-7.0630Upcoming EarningsARDXArdelyx4.3366 of 5 stars$4.39+1.4%$10.88+147.7%-8.6%$1.04B$333.61M-19.9590Earnings ReportAnalyst UpgradeGPCRStructure Therapeutics1.8152 of 5 stars$16.78-4.6%$76.17+353.9%-51.7%$1.01BN/A-19.29136Trending NewsEarnings ReportAnalyst RevisionAMPHAmphastar Pharmaceuticals3.2697 of 5 stars$21.40+0.9%$32.33+51.1%-44.4%$999.82M$731.97M7.752,028Analyst ForecastGap UpVERVVerve Therapeutics2.8913 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110Upcoming EarningsSYRESpyre Therapeutics2.4079 of 5 stars$16.16-0.6%$53.40+230.4%-38.9%$980.08M$890K-4.2973Positive NewsEarnings ReportAKBAAkebia Therapeutics3.9453 of 5 stars$3.76+1.1%$6.75+79.5%+208.1%$977.01M$160.18M-17.90430RCUSArcus Biosciences2.3298 of 5 stars$9.22+0.6%$21.29+131.0%-41.8%$969.91M$258M-2.20500Trending NewsEarnings ReportAnalyst UpgradeAnalyst RevisionCOLLCollegium Pharmaceutical2.9249 of 5 stars$31.09+3.4%$43.75+40.7%-1.6%$966.20M$631.45M25.48210Analyst Upgrade Related Companies and Tools Related Companies PAHC Alternatives PHVS Alternatives ARDX Alternatives GPCR Alternatives AMPH Alternatives VERV Alternatives SYRE Alternatives AKBA Alternatives RCUS Alternatives COLL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ADCT) was last updated on 8/11/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADC Therapeutics SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ADC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.